肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

胰腺癌新突破：G-CSF抑制剂有望逆转胰腺癌！

2017-09-04 佚名 medicalxpress

胰腺癌G-CSF
关注

胰腺导管癌指的是始于胰腺导管上皮或腺泡细胞的实质性癌，也是胰腺肿瘤中最多见者。胰腺导管癌(PDAC)是最致命的癌症之一，有些研究表示，慢性胰腺炎和糖尿病是胰腺癌的病因所在，也有些研究并不支持这一观点。

【胰腺癌治疗新发展】胰腺导管癌指的是始于胰腺导管上皮或腺泡细胞的实质性癌，也是胰腺肿瘤中最多见者。胰腺导管癌(PDAC)是最致命的癌症之一，有些研究表示，慢性胰腺炎和糖尿病是胰腺癌的病因所在，也有些研究并不支持这一观点。据统计，同年龄组糖尿病病人的胰腺癌发病率为非糖尿病者的2～3倍，胰腺导管癌的治疗效果并不佳，因此新的治疗方法一直都在需求中。

目前，谢尔盖医学博士和他的同事们对胰腺导管癌小鼠进行了试验，调查了它们的免疫反应，研究人员发现胰腺上皮高浓度的g - csf(也就是粒细胞集落刺激因子)在胰腺上皮的作用，成熟的高浓度的粒细胞集落刺激因子增强了免疫细胞表达消灭肿瘤细胞的能力，助长了胰腺癌细胞的扩散。研究人员确定人类癌症基因组图谱和组织微阵列的数据也存在同样的情况。

抑制粒细胞集落刺激因子，结合使用抑制性抗体的化疗药物吉西他滨可以减少肿瘤大小，减少免疫抑制细胞的数量，并且有效增加浸润T细胞的数量，这一结果，比单独使用吉西他滨治疗，效果显着增加。

完整的研究报告发表于《癌症免疫学》杂志中，研究人员在报告中表明，对抗粒细胞集落刺激因子的治疗方法可以增加在胰腺导管癌常规化疗的有效性，显着提供胰腺导管癌患者的生存期。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851518, encodeId=941218515189a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 26 02:26:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724943, encodeId=8cfd1e24943ed, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sun Apr 01 00:26:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028138, encodeId=17622028138bb, content=<a href='/topic/show?id=c1a4e76382' target=_blank style='color:#2F92EE;'>#G-CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7763, encryptionId=c1a4e76382, topicName=G-CSF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun May 13 09:26:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668846, encodeId=5ad21668846db, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sat Jan 20 02:26:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240842, encodeId=0ab3240842d4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:52:53 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2018-07-26 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1851518, encodeId=941218515189a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 26 02:26:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724943, encodeId=8cfd1e24943ed, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sun Apr 01 00:26:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028138, encodeId=17622028138bb, content=<a href='/topic/show?id=c1a4e76382' target=_blank style='color:#2F92EE;'>#G-CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7763, encryptionId=c1a4e76382, topicName=G-CSF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun May 13 09:26:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668846, encodeId=5ad21668846db, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sat Jan 20 02:26:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240842, encodeId=0ab3240842d4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:52:53 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2018-04-01 zxxiang

    #新突破#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851518, encodeId=941218515189a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 26 02:26:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724943, encodeId=8cfd1e24943ed, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sun Apr 01 00:26:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028138, encodeId=17622028138bb, content=<a href='/topic/show?id=c1a4e76382' target=_blank style='color:#2F92EE;'>#G-CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7763, encryptionId=c1a4e76382, topicName=G-CSF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun May 13 09:26:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668846, encodeId=5ad21668846db, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sat Jan 20 02:26:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240842, encodeId=0ab3240842d4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:52:53 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2018-05-13 30397604

    #G-CSF#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1851518, encodeId=941218515189a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 26 02:26:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724943, encodeId=8cfd1e24943ed, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sun Apr 01 00:26:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028138, encodeId=17622028138bb, content=<a href='/topic/show?id=c1a4e76382' target=_blank style='color:#2F92EE;'>#G-CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7763, encryptionId=c1a4e76382, topicName=G-CSF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun May 13 09:26:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668846, encodeId=5ad21668846db, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sat Jan 20 02:26:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240842, encodeId=0ab3240842d4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:52:53 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2018-01-20 kcb078

    #CSF#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1851518, encodeId=941218515189a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jul 26 02:26:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724943, encodeId=8cfd1e24943ed, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sun Apr 01 00:26:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028138, encodeId=17622028138bb, content=<a href='/topic/show?id=c1a4e76382' target=_blank style='color:#2F92EE;'>#G-CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7763, encryptionId=c1a4e76382, topicName=G-CSF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun May 13 09:26:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668846, encodeId=5ad21668846db, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sat Jan 20 02:26:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240842, encodeId=0ab3240842d4, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Tue Sep 05 22:52:53 CST 2017, time=2017-09-05, status=1, ipAttribution=)]
    2017-09-05 luominglian113

    学习了.谢谢分享

    0

相关资讯

Sci Rep：不同类型胰腺癌细胞中KRAS突变的异质性

胰腺导管腺癌（PDAC）是一种破坏性疾病，血液中的循环肿瘤细胞（CTC）被认为是全身肿瘤扩散的手段。PDAC是美国和欧洲癌症相关死亡的第四大原因，发生率几乎等于死亡率，5年生存率<6％。这主要是由于其在转移期经常晚期诊断，具侵袭性，并仅对部分已知化学疗法应答。

神奇！智能手机自拍竟能筛查胰腺癌

胰腺癌预后不佳，五年生存率仅为9%，部分原因是因为没有指示症状或非侵入性筛查工具在肿瘤传播之前识别肿瘤。现在，华盛顿大学（UW）的研究人员开发了一个可以让人们轻松筛查胰腺癌和其他疾病的应用程序——通过智能手机拍摄个人自拍照。

Gastroenterol:广州医科大学唐道林教授团队发现治疗胰腺癌的新药物和新机制

近日，广州医科大学附属第三医院特聘教授唐道林带领的团队，在胰腺癌的治疗领域取得了突破性进展，他们不仅发现了一种新的胰腺癌药物，还阐明了程序性坏死的新型调控分子机制。 对于缺医少药，且表现极度恶劣的胰腺癌而言，唐教授团队的新发现显得弥足珍贵。相关的研究成果刊登在消化领域顶级期刊《肠胃病学》（胃肠病学研究排名第1的期刊，2016年影响因子为18.392）上

2030年胰腺癌将成全球第二大致死癌症，突发糖尿病要警惕

胰腺癌是消化系统恶性程度最高的肿瘤之一，被称为“癌中之王”。全球范围内胰腺癌的发病率和死亡率分别列恶性肿瘤的第12位和第7位。其发病率高、病情进展快，且患者发病时大多已处于晚期，病死率极高。在我国，胰腺癌呈快速上升趋势，农村地区尤为突出。如何进一步提高胰腺癌患者生活质量和延长生存期成为大众的关注热点。8月26日，在刚刚开幕的“第二届中国胰腺肿瘤大会”上，大会执行主席、上海交通大学医学院附属仁济医院

Int J Cancer：尿前列腺素E2代谢产物与胰腺癌风险的前瞻性研究

环氧合酶2（COX-2）通路在许多胰腺癌细胞中的表达是上升的，前列腺素E2（PGE2）作为COX-2催化花生四烯酸而产生的中间产物，在多种肿瘤中表达显著增加，且与肿瘤的发展相关。因此，有人认为COX-2上调的致癌作用主要是通过前列腺素E2（PGE2）的生产过剩造成的。来自美国的研究小组通过评估尿PGE2代谢物(PGE-M，体内PGE2生产过剩的一种生物标志物)和胰腺癌风险之间的相关性来验证这一假说

JCO：吉西他滨+厄洛替尼辅助治疗胰腺导管腺癌，患者能否获益？

胰腺导管腺癌是一类预后非常差的恶性肿瘤，缺乏有效的治疗靶点。在晚期胰腺癌中发现，吉西他滨联合厄洛替尼，相比吉西他滨单药显着延长OS。基于此，进行了CONKO-005研究，旨在R0切除术后的胰腺导管腺癌中，探索吉西他滨联合厄洛替尼对比吉西他滨单药，能否给患者带来生存获益。